Cargando…

Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid

This study examines the effect of co‐administration of antimicrobial peptides and the synthetic glycolipid FP7, which is active in inhibiting inflammatory cytokine production caused by TLR4 activation and signaling. The co‐administration of two lipopolysaccharide (LPS)‐neutralizing peptides (a cecro...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchini, Fabio A., Coelho, Helena, Sestito, Stefania E., Delgado, Sandra, Minotti, Alberto, Andreu, David, Jiménez‐Barbero, Jesús, Peri, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900894/
https://www.ncbi.nlm.nih.gov/pubmed/29265636
http://dx.doi.org/10.1002/cmdc.201700694
_version_ 1783314501520588800
author Facchini, Fabio A.
Coelho, Helena
Sestito, Stefania E.
Delgado, Sandra
Minotti, Alberto
Andreu, David
Jiménez‐Barbero, Jesús
Peri, Francesco
author_facet Facchini, Fabio A.
Coelho, Helena
Sestito, Stefania E.
Delgado, Sandra
Minotti, Alberto
Andreu, David
Jiménez‐Barbero, Jesús
Peri, Francesco
author_sort Facchini, Fabio A.
collection PubMed
description This study examines the effect of co‐administration of antimicrobial peptides and the synthetic glycolipid FP7, which is active in inhibiting inflammatory cytokine production caused by TLR4 activation and signaling. The co‐administration of two lipopolysaccharide (LPS)‐neutralizing peptides (a cecropin A–melittin hybrid peptide and a human cathelicidin) enhances by an order of magnitude the potency of FP7 in blocking the TLR4 signal. Interestingly, this is not an additional effect of LPS neutralization by peptides, because it also occurs if cells are stimulated by the plant lectin phytohemagglutinin, a non‐LPS TLR4 agonist. Our data suggest a dual mechanism of action for the peptides, not exclusively based on LPS binding and neutralization, but also on a direct effect on the LPS‐binding proteins of the TLR4 receptor complex. NMR experiments in solution show that peptide addition changes the aggregation state of FP7, promoting the formation of larger micelles. These results suggest a relationship between the aggregation state of lipid A‐like ligands and the type and intensity of the TLR4 response.
format Online
Article
Text
id pubmed-5900894
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59008942018-04-23 Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid Facchini, Fabio A. Coelho, Helena Sestito, Stefania E. Delgado, Sandra Minotti, Alberto Andreu, David Jiménez‐Barbero, Jesús Peri, Francesco ChemMedChem Full Papers This study examines the effect of co‐administration of antimicrobial peptides and the synthetic glycolipid FP7, which is active in inhibiting inflammatory cytokine production caused by TLR4 activation and signaling. The co‐administration of two lipopolysaccharide (LPS)‐neutralizing peptides (a cecropin A–melittin hybrid peptide and a human cathelicidin) enhances by an order of magnitude the potency of FP7 in blocking the TLR4 signal. Interestingly, this is not an additional effect of LPS neutralization by peptides, because it also occurs if cells are stimulated by the plant lectin phytohemagglutinin, a non‐LPS TLR4 agonist. Our data suggest a dual mechanism of action for the peptides, not exclusively based on LPS binding and neutralization, but also on a direct effect on the LPS‐binding proteins of the TLR4 receptor complex. NMR experiments in solution show that peptide addition changes the aggregation state of FP7, promoting the formation of larger micelles. These results suggest a relationship between the aggregation state of lipid A‐like ligands and the type and intensity of the TLR4 response. John Wiley and Sons Inc. 2018-01-24 2018-02-06 /pmc/articles/PMC5900894/ /pubmed/29265636 http://dx.doi.org/10.1002/cmdc.201700694 Text en © 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Full Papers
Facchini, Fabio A.
Coelho, Helena
Sestito, Stefania E.
Delgado, Sandra
Minotti, Alberto
Andreu, David
Jiménez‐Barbero, Jesús
Peri, Francesco
Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
title Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
title_full Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
title_fullStr Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
title_full_unstemmed Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
title_short Co‐administration of Antimicrobial Peptides Enhances Toll‐like Receptor 4 Antagonist Activity of a Synthetic Glycolipid
title_sort co‐administration of antimicrobial peptides enhances toll‐like receptor 4 antagonist activity of a synthetic glycolipid
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900894/
https://www.ncbi.nlm.nih.gov/pubmed/29265636
http://dx.doi.org/10.1002/cmdc.201700694
work_keys_str_mv AT facchinifabioa coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT coelhohelena coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT sestitostefaniae coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT delgadosandra coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT minottialberto coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT andreudavid coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT jimenezbarberojesus coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid
AT perifrancesco coadministrationofantimicrobialpeptidesenhancestolllikereceptor4antagonistactivityofasyntheticglycolipid